CASI Pharmaceuticals, Inc. (CASI)
- Previous Close
2.2400 - Open
2.1800 - Bid 2.2200 x 100
- Ask --
- Day's Range
2.1800 - 2.3000 - 52 Week Range
1.8500 - 8.4800 - Volume
10,084 - Avg. Volume
208,493 - Market Cap (intraday)
30.153M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0200 - Earnings Date Apr 24, 2024 - Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
www.casipharmaceuticals.comRecent News: CASI
Performance Overview: CASI
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CASI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CASI
Valuation Measures
Market Cap
29.62M
Enterprise Value
20.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.87
Price/Book (mrq)
1.23
Enterprise Value/Revenue
0.59
Enterprise Value/EBITDA
-0.93
Financial Highlights
Profitability and Income Statement
Profit Margin
-79.51%
Return on Assets (ttm)
-18.42%
Return on Equity (ttm)
-57.65%
Revenue (ttm)
33.88M
Net Income Avi to Common (ttm)
-26.96M
Diluted EPS (ttm)
-2.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
30.77M
Total Debt/Equity (mrq)
87.89%
Levered Free Cash Flow (ttm)
-13.71M